Business Wire

CA-OPTIV-SECURITY

Share
Optiv Security Announces New Risk Transformation Service™ to Help Organizations Mitigate Enterprise Risk

Most organizations conduct annual risk assessments, identify gaps, and receive recommendations for how to remediate those gaps. But many lack the resources to follow through on planning and operationalization. Based on strategies developed or assessments performed, many organizations know what to do but often not how to do it. Optiv Security , the world’s leading security solutions integrator, today announced its new Risk Transformation ServiceTM , an end-to-end solution that includes strategy execution.

Designed to enable clients around the world to better evaluate current risk against acceptable risk, Optiv’s Risk Transformation ServiceTM helps clients develop strategies that drive cohesive cybersecurity programs, execute on those strategies to mitigate enterprise risk, and achieve measurable outcomes. The service puts business strategy and risk at the heart of cyber decision-making with two distinct options:

  • The Enterprise Risk Transformation Service TM helps organizations execute on risk transformation based on business objectives, results of an existing strategy or assessment, and a list of desired improvements or future mode of operation. This service includes program management, quality assurance and oversight over all or parts of a transformation or remediation initiative.
  • The Quickstart Risk Transformation Service TM enables mid-sized organizations to get started with a risk-centric model for cybersecurity and aids them in the first steps of execution of their transformation roadmap. Optiv helps these clients set and execute a strategy, engaging with them from start to finish.

“Organizations today are adopting new risk and compliance principles to achieve business resilience,” said Dustin Owens, Optiv’s vice president, risk advisory. “As IT risk management evolves to more holistic operational risk management, it is being integrated into the fabric of organizations. This means that security teams are now a critical component to the overall business risk strategy.”

Owens continued, “As a result, adaptive, risk-based decision-making is becoming core to business agility and resilience, taking over from the antiquated check-the-box, compliance-based approach of the past. It’s high time for companies to embrace the risk revolution. They need to take a stance against the outside-in approach – which is predicated on continuously responding to legislative and regulatory requirements, specific threats, and other outside factors – and rewrite how they manage cybersecurity by proactively addressing all aspects of cybersecurity risk, including privacy and governance , cyber resilience, and risk optimization.”

Optiv’s new Risk Transformation ServiceTM is part of the company’s complete continuum of fully integrated cybersecurity risk services, which are focused on resolving three prevalent business issues:

  • The need for risk governance – Optiv helps clients understand where critical assets are located, why they are important, how they are protected and who has access; and as these variables change, how their risk profile changes. This enables organizations to make security decisions based on risk so they can move faster, safely.
  • Volume and velocity of change – Optiv allows clients to embrace the fast pace of digital transformation initiatives and deal with constant operational chaos simultaneously by helping them execute adaptive cyber resilience capabilities.
  • Articulating security health to the business and board – Optiv provides security teams with everything they need to articulate risk and security performance in business terms by enabling them to effectively measure, monitor and report on security posture and align security to business objectives. This allows security teams to influence better decision-making and improve overall business health.

Please visit Optiv’s website to learn more about risk transformation or the company’s overarching approach to risk management .

Follow Optiv
Twitter: www.twitter.com/optiv
LinkedIn: www.linkedin.com/company/optiv-inc
Facebook: www.facebook.com/optivinc
YouTube: www.youtube.com/c/OptivInc
Blog: www.optiv.com/explore-optiv-insights/blog

About Optiv Security

Optiv helps clients plan, build and run successful cybersecurity programs that achieve business objectives through our depth and breadth of cybersecurity offerings, extensive capabilities and proven expertise in cybersecurity, integration and cyber operational services. Optiv maintains premium partnerships with more than 350 of the leading cybersecurity technology manufacturers. For more information, visit www.optiv.com .

Contact:

Brett Ater (913) 304-7683 Brett.ater@optiv.com or Jason Cook (816) 701-3374 Jason.cook@optiv.com

Link:

ClickThru

Social Media:

https://www.facebook.com/OptivInc

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye